Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2017

Ou Sai-Hong Ignatius, Young Lauren, Schrock Alexa B, Johnson Adrienne, Klempner Samuel J, Zhu Viola W, Miller Vincent A, Ali Siraj M

Abstract excerpt

INTRODUCTION: MET proto-oncogene, receptor tyrosine kinase gene exon 14 skipping (METex14) alterations represent a unique subset of oncogenic drivers in NSCLC. Preliminary clinical activity of crizotinib against METex14-positive NSCLC has been reported. The full spectrum of resistance mechanisms to crizotinib in METex14-positive NSCLC remains to be identified. METHODS: Hybrid capture-based comprehensive genomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Crizotinib

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Neoplasm Staging

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Pyridines

Source

Identifiers

PMID: 27666659
DOI: 10.1016/j.jtho.2016.09.119

Genes

MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.PMID 27666659Read ↗

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.Semantic proximity Read ↗

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 studySemantic proximity Read ↗

Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung CancerSemantic proximity Read ↗

Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinibSemantic proximity Read ↗

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.Semantic proximity Read ↗

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 SkippingSemantic proximity Read ↗

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutationsSemantic proximity Read ↗

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in <i>MET</i> exon 14 skipping mutation positive lung cancerSemantic proximity Read ↗

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective StudySemantic proximity Read ↗

Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.Semantic proximity Read ↗

Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.